Wendy Erber

I am a highly passionate early career research associate with an emerging international reputation in the development of advanced cell analysis technology and cutting-edge methodologies for both research and clinical applications. Since 2013, I have been key to the expansion of an award-winning, multi-disciplinary research team that leads the world in imaging flow cytometry powered diagnostic developments for haematological malignancies and blood-based disorders. I am the co-inventor of the world-first “Immuno-flowFISH” method, a game-changing diagnostic technology. This invention enables precision assessment of blood cancers that vastly exceeds current research and clinical testing modalities. In 2018, I was awarded the awarded the highly prestigious ANSTO 2018 Eureka Prize for Innovative Use of Technology by the Australian Museum. My research has patented in many countries and my world-leading expertise has drawn investment and funding equivalent to $3.4M in value from industry partnerships, government grants and health-care organisations. I have established global collaborative networks with both industry leading medical technology corporations (Sysmex Corporation, Japan) and world-class diagnostic cancer centers (MD Anderson Cancer Centre, Texas USA and Addenbrooke’s Hospital, Cambridge, UK). I am currently leading the translational beta testing and commercialisation of immuno-flowFISH through this multi-disciplinary collaborative network to establish global adoption of this technology. My long-term goal as a scientist is to lead the innovation, application, influence, education, engagement and outreach of medical research in both scientific and clinical domains, to advance knowledge and health globally.